Hutchmed: Phase III Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

  Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints —

— Overall safety consistent with sovleplenib known profile —

— Plans for regulatory submission underway in China, where it was designated a Breakthrough Therapy —

— Results to be submitted to an upcoming medical meeting —

https://finance.yahoo.com/news/hutchmed-announces-sovleplenib-phase-iii-000000766.html